1001667-23-7 Usage
General Description
ACH 0141625 is a chemical compound that has been studied for its potential as a treatment for inflammatory and autoimmune diseases, as well as cancer. It is a potent and selective inhibitor of Janus kinase 1 (JAK1), which plays a key role in the signaling pathways that regulate immune responses and inflammation. By inhibiting JAK1, ACH 0141625 has the potential to reduce the production of inflammatory cytokines and suppress the overactive immune response seen in many autoimmune diseases. Additionally, ACH 0141625 has shown promise in preclinical studies for its ability to inhibit the growth of cancer cells, making it a potentially important compound for the development of novel therapeutics for a range of diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 1001667-23-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,1,6,6 and 7 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1001667-23:
(9*1)+(8*0)+(7*0)+(6*1)+(5*6)+(4*6)+(3*7)+(2*2)+(1*3)=97
97 % 10 = 7
So 1001667-23-7 is a valid CAS Registry Number.
1001667-23-7Relevant articles and documents
4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
-
Page/Page column 45; 46; 69; 70, (2015/10/05)
The invention provides 4-amino-4-oxobutanoyl peptides of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R1, R6-R8, R16, R18, R19, M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. The 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptides and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptides as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptides and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.